DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Adalimumab in Adult Japanese Subjects With Psoriasis

Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis

Intervention: adalimumab (Biological); adalimumab (Biological)

Phase: Phase 2/Phase 3

Status: Active, not recruiting

Sponsored by: Abbott

Official(s) and/or principal investigator(s):
Noritaka Inomata, Ph.D., Study Director, Affiliation: Abbott

Summary

To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with psoriasis

Clinical Details

Official title: A Multicenter Open-Label Continuation Study of the Long-Term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study design: Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study

Primary outcome: PASI 50 Response

Secondary outcome:

PASI75/90

Incidence of AEs

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects who completed study M04-688

Exclusion Criteria:

- Subject is considered by the investigator, for any reason, to be an unsuitable

candidate for the study

Locations and Contacts

Hokkaido, Japan

Iwate, Japan

Miyagi, Japan

Fukushima, Japan

Tochigi, Japan

Chiba, Japan

Tokyo, Japan

Kanagawa, Japan

Ishikawa, Japan

Gifu, Japan

Shizuoka, Japan

Aichi, Japan

Mie, Japan

Kyoto, Japan

Osaka, Japan

Hyogo, Japan

Okayama, Japan

Hiroshima, Japan

Yamaguchi, Japan

Tokushima, Japan

Kochi, Japan

Fukuoka, Japan

Nagasaki, Japan

Kagoshima, Japan

Additional Information

Starting date: April 2006
Last updated: March 27, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012